JP2008518013A - プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法 - Google Patents

プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法 Download PDF

Info

Publication number
JP2008518013A
JP2008518013A JP2007539030A JP2007539030A JP2008518013A JP 2008518013 A JP2008518013 A JP 2008518013A JP 2007539030 A JP2007539030 A JP 2007539030A JP 2007539030 A JP2007539030 A JP 2007539030A JP 2008518013 A JP2008518013 A JP 2008518013A
Authority
JP
Japan
Prior art keywords
colitis
prostaglandin
compound
agonist
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007539030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008518013A5 (enExample
Inventor
ファ・ビン・イム
ヤリフ・ドンド
マーク・ホロボスキー
デイビッド・ダブリュー・オールド
カレン・エム・ケジー
ダニエル・ダブリュー・ギル
ジョン・イー・ドネロ
ロバート・エム・バーク
トッド・エス・ガック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2008518013A publication Critical patent/JP2008518013A/ja
Publication of JP2008518013A5 publication Critical patent/JP2008518013A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007539030A 2004-10-26 2005-10-24 プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法 Pending JP2008518013A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62242204P 2004-10-26 2004-10-26
PCT/US2005/038303 WO2006047476A2 (en) 2004-10-26 2005-10-24 Therapeutic and delivery methods of prostaglandin ep4 agonists

Publications (2)

Publication Number Publication Date
JP2008518013A true JP2008518013A (ja) 2008-05-29
JP2008518013A5 JP2008518013A5 (enExample) 2008-12-25

Family

ID=35840538

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007539030A Pending JP2008518013A (ja) 2004-10-26 2005-10-24 プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法

Country Status (7)

Country Link
US (1) US20080132543A1 (enExample)
EP (1) EP1805139A2 (enExample)
JP (1) JP2008518013A (enExample)
AU (1) AU2005299473B2 (enExample)
BR (1) BRPI0518242A2 (enExample)
CA (1) CA2585367A1 (enExample)
WO (1) WO2006047476A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006052893A2 (en) * 2004-11-08 2006-05-18 Allergan, Inc. Substituted pyrrolidone compounds as ep4 agonists
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
JP2010513551A (ja) * 2006-12-18 2010-04-30 アラーガン インコーポレイテッド 胃腸疾患の治療方法および組成物
EP3533445A1 (en) 2009-03-19 2019-09-04 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
US20120190637A1 (en) 2009-10-14 2012-07-26 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
CN103167876B (zh) 2010-08-12 2016-08-31 菲特治疗公司 改进的造血干细胞和祖细胞疗法
US20120259413A1 (en) * 2011-04-07 2012-10-11 Allergan, Inc. Devices, compositions and methods utilizing ep4 and ep2 receptor agonists for preventing, reducing or treating capsular contracture
CA2850484C (en) 2011-09-30 2021-01-26 Bluebird Bio, Inc. Compounds for improved viral transduction
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
CN104066837B (zh) 2011-12-02 2020-12-08 菲特治疗公司 增强的干细胞组合物
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
CA2920856C (en) 2013-08-09 2026-03-03 Ardelyx, Inc. Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
KR20250134722A (ko) 2016-02-12 2025-09-11 블루버드 바이오, 인코포레이티드. Vcn 인핸서 조성물 및 이의 사용 방법
CN108883136A (zh) 2016-02-12 2018-11-23 蓝鸟生物公司 Vcn增强子组合物及其使用方法
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063158A1 (en) * 2003-01-10 2004-07-29 F.Hoffmann-La Roche Ag 2-piperidone derivatives as prostaglandin agonists
WO2004071428A2 (en) * 2003-02-11 2004-08-26 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
WO2004085430A1 (en) * 2003-03-26 2004-10-07 Merck Frosst Canada Ltd. Prostaglandin analogs as ep4 receptor agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5714346B2 (enExample) * 1973-07-12 1982-03-24
KR880012221A (ko) * 1987-04-13 1988-11-26 사노 가즈오 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
US6043275A (en) * 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
EP1114816A4 (en) * 1998-09-14 2002-09-04 Ono Pharmaceutical Co SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT
US20020002140A1 (en) * 2000-01-14 2002-01-03 Holick Michael F. Novel bisphosphonates and uses thereof
EA200300379A1 (ru) * 2000-11-27 2003-08-28 Пфайзер Продактс Инк. Селективные агонисты рецептора ep4 в лечении остеопороза
US20030027853A1 (en) * 2001-06-14 2003-02-06 Allergan Sales, Inc. 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US20050222094A1 (en) * 2001-06-14 2005-10-06 Burk Robert M Treatment of inflammatory bowel disease
JP2004521954A (ja) * 2001-07-16 2004-07-22 エフ．ホフマン−ラ　ロシュ　アーゲー Ｅｐ４受容体作用薬としてのプロスタグランジン類似体
JP4273407B2 (ja) * 2001-07-23 2009-06-03 小野薬品工業株式会社 Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤
ATE336247T1 (de) * 2002-03-18 2006-09-15 Pfizer Prod Inc Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
US6875787B2 (en) * 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063158A1 (en) * 2003-01-10 2004-07-29 F.Hoffmann-La Roche Ag 2-piperidone derivatives as prostaglandin agonists
WO2004071428A2 (en) * 2003-02-11 2004-08-26 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
WO2004085430A1 (en) * 2003-03-26 2004-10-07 Merck Frosst Canada Ltd. Prostaglandin analogs as ep4 receptor agonists

Also Published As

Publication number Publication date
AU2005299473A1 (en) 2006-05-04
WO2006047476A3 (en) 2006-09-28
US20080132543A1 (en) 2008-06-05
AU2005299473B2 (en) 2012-06-28
BRPI0518242A2 (pt) 2008-11-11
EP1805139A2 (en) 2007-07-11
CA2585367A1 (en) 2006-05-04
WO2006047476A2 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
AU2007233285B2 (en) Prostaglandin EP4 agonists
AU2005299473B2 (en) Therapeutic and delivery methods of prostaglandin EP4 agonists
EP0662075B1 (en) Prostaglandin analog for treating osteoporosis
HU230190B1 (hu) Glikopeptidszármazékok és ezeket tartalmazó gyógyászati kompozíciók
EP0985663A1 (en) A 3.7-dithiaprostanoic acid derivative
US7893107B2 (en) Therapeutic methods using prostaglandin EP4 agonist components
EP1049721A1 (fr) Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
EP1817033B1 (en) Treatment of inflammatory bowel disease
CN111712507B (zh) 改良药物口服生物有效性的方法
KR20010041358A (ko) 표적 장기 이행성 담체 폴리머 및 약물 함유 폴리머
JPH11513061A (ja) 合成ポリサッカライド、それらの製造法およびそれらを含む医薬組成物
EP1871381B1 (en) Therapeutic substituted cyclopentanones
AU2012227306A1 (en) Therapeutic and delivery methods of prostaglandin EP4 agonists
US20060166927A1 (en) Compounds that bind to the interferon-gamma, preparation method thereof and medicaments containing same
WO2011013398A1 (ja) Cd22分子に対する高親和性を有しｂ細胞の増殖を増強する化合物
JP2021161092A (ja) 新規ｃｄｐ−リビトール誘導体
JPWO1999043736A1 (ja) 標的臓器移行性担体ポリマーおよび薬物含有ポリマー

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080401

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20080401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080409

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111004

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130115